IFNG and neoplasm: Otherwise, an immunotherapeutic combination using the STAT1-activating IFN-γ, the TLR3 ligand poly(I:C), and an anti-IL-10 antibody can be used to convert the microenvironment to a more favourable configuration and sensitise murine tumours to ICB by attracting IFN-γ -producing nature killer (NK) cells41.